Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 3
1988 10
1989 10
1990 10
1991 8
1992 2
1993 4
1994 9
1995 2
1996 6
1997 7
1998 5
1999 2
2000 4
2001 5
2002 5
2003 7
2004 5
2005 5
2006 7
2007 7
2008 9
2009 4
2010 13
2011 12
2012 10
2013 13
2014 19
2015 23
2016 25
2017 21
2018 34
2019 31
2020 26
2021 31
2022 36
2023 39

Text availability

Article attribute

Article type

Publication date

Search Results

410 results

Results by year

Filters applied: . Clear all
Page 1
Immunotherapies for hepatocellular carcinoma.
Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX, Finn RS. Llovet JM, et al. Among authors: mazzaferro v. Nat Rev Clin Oncol. 2022 Mar;19(3):151-172. doi: 10.1038/s41571-021-00573-2. Epub 2021 Nov 11. Nat Rev Clin Oncol. 2022. PMID: 34764464 Review.
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.
Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. Reig M, et al. Among authors: mazzaferro v. J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19. J Hepatol. 2022. PMID: 34801630 Free PMC article. Review.
Sorafenib in advanced hepatocellular carcinoma.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Llovet JM, et al. Among authors: mazzaferro v. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857. N Engl J Med. 2008. PMID: 18650514 Free article. Clinical Trial.
Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference.
Mehta N, Bhangui P, Yao FY, Mazzaferro V, Toso C, Akamatsu N, Durand F, Ijzermans J, Polak W, Zheng S, Roberts JP, Sapisochin G, Hibi T, Kwan NM, Ghobrial M, Soin A. Mehta N, et al. Among authors: mazzaferro v. Transplantation. 2020 Jun;104(6):1136-1142. doi: 10.1097/TP.0000000000003174. Transplantation. 2020. PMID: 32217938 Free article. Review.
DNA Methylation Profiling of Human Hepatocarcinogenesis.
Hernandez-Meza G, von Felden J, Gonzalez-Kozlova EE, Garcia-Lezana T, Peix J, Portela A, Craig AJ, Sayols S, Schwartz M, Losic B, Mazzaferro V, Esteller M, Llovet JM, Villanueva A. Hernandez-Meza G, et al. Among authors: mazzaferro v. Hepatology. 2021 Jul;74(1):183-199. doi: 10.1002/hep.31659. Epub 2021 Jun 15. Hepatology. 2021. PMID: 33237575 Free PMC article.
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma.
Haber PK, Castet F, Torres-Martin M, Andreu-Oller C, Puigvehí M, Miho M, Radu P, Dufour JF, Verslype C, Zimpel C, Marquardt JU, Galle PR, Vogel A, Bathon M, Meyer T, Labgaa I, Digklia A, Roberts LR, Mohamed Ali MA, Mínguez B, Citterio D, Mazzaferro V, Finkelmeier F, Trojan J, Özdirik B, Müller T, Schmelzle M, Bejjani A, Sung MW, Schwartz ME, Finn RS, Thung S, Villanueva A, Sia D, Llovet JM. Haber PK, et al. Among authors: mazzaferro v. Gastroenterology. 2023 Jan;164(1):72-88.e18. doi: 10.1053/j.gastro.2022.09.005. Epub 2022 Sep 12. Gastroenterology. 2023. PMID: 36108710 Free article.
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
Martin-Serrano MA, Kepecs B, Torres-Martin M, Bramel ER, Haber PK, Merritt E, Rialdi A, Param NJ, Maeda M, Lindblad KE, Carter JK, Barcena-Varela M, Mazzaferro V, Schwartz M, Affo S, Schwabe RF, Villanueva A, Guccione E, Friedman SL, Lujambio A, Tocheva A, Llovet JM, Thung SN, Tsankov AM, Sia D. Martin-Serrano MA, et al. Among authors: mazzaferro v. Gut. 2023 Apr;72(4):736-748. doi: 10.1136/gutjnl-2021-326514. Epub 2022 May 18. Gut. 2023. PMID: 35584893
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.
Montironi C, Castet F, Haber PK, Pinyol R, Torres-Martin M, Torrens L, Mesropian A, Wang H, Puigvehi M, Maeda M, Leow WQ, Harrod E, Taik P, Chinburen J, Taivanbaatar E, Chinbold E, Solé Arqués M, Donovan M, Thung S, Neely J, Mazzaferro V, Anderson J, Roayaie S, Schwartz M, Villanueva A, Friedman SL, Uzilov A, Sia D, Llovet JM. Montironi C, et al. Among authors: mazzaferro v. Gut. 2023 Jan;72(1):129-140. doi: 10.1136/gutjnl-2021-325918. Epub 2022 Feb 23. Gut. 2023. PMID: 35197323 Free PMC article.
Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma.
Esteban-Fabró R, Willoughby CE, Piqué-Gili M, Montironi C, Abril-Fornaguera J, Peix J, Torrens L, Mesropian A, Balaseviciute U, Miró-Mur F, Mazzaferro V, Pinyol R, Llovet JM. Esteban-Fabró R, et al. Among authors: mazzaferro v. Clin Cancer Res. 2022 Jun 1;28(11):2449-2460. doi: 10.1158/1078-0432.CCR-21-2517. Clin Cancer Res. 2022. PMID: 35302601 Free PMC article.
410 results